A detailed history of Amalgamated Bank transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 2,396 shares of MCRB stock, worth $1,725. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,396
Previous 11,122 78.46%
Holding current value
$1,725
Previous $16,000 87.5%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$0.75 - $1.56 $6,544 - $13,612
-8,726 Reduced 78.46%
2,396 $2,000
Q4 2023

Feb 06, 2024

SELL
$0.93 - $2.15 $663 - $1,532
-713 Reduced 6.02%
11,122 $16,000
Q2 2023

Aug 11, 2023

BUY
$4.67 - $6.55 $9,652 - $13,538
2,067 Added 21.16%
11,835 $56,000
Q1 2023

May 02, 2023

SELL
$4.95 - $6.09 $7,306 - $8,988
-1,476 Reduced 13.13%
9,768 $55,000
Q3 2022

Nov 09, 2022

BUY
$3.5 - $7.2 $626 - $1,288
179 Added 1.62%
11,244 $72,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $7.62 $720 - $2,034
-267 Reduced 2.36%
11,065 $38,000
Q1 2022

Jun 30, 2022

SELL
$6.3 - $8.84 $6,022 - $8,451
-956 Reduced 7.78%
11,332 $81,000
Q4 2021

Feb 15, 2022

SELL
$6.02 - $11.43 $2,034 - $3,863
-338 Reduced 2.68%
12,288 $102,000
Q3 2021

Oct 29, 2021

SELL
$5.46 - $22.6 $2,822 - $11,684
-517 Reduced 3.93%
12,626 $88,000
Q2 2021

Aug 16, 2021

BUY
$18.46 - $24.36 $242,619 - $320,163
13,143 New
13,143 $313,000
Q1 2021

May 13, 2021

SELL
$17.66 - $28.92 $152,246 - $249,319
-8,621 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$23.25 - $37.73 $8,532 - $13,846
367 Added 4.45%
8,621 $211,000
Q3 2020

Oct 30, 2020

BUY
$3.74 - $28.74 $30,869 - $237,219
8,254 New
8,254 $234,000

Others Institutions Holding MCRB

About Seres Therapeutics, Inc.


  • Ticker MCRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,072,000
  • Market Cap $89.3M
  • Description
  • Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...
More about MCRB
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.